Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma Our study included a broad cohort of ...

This predictive model built on readily acquired clinical data provides encouraging results for the detection of residual disease. External validation and prospective studies implementing the model in ...